Alioth Biotech Secures ￥100M+ in Pre-B Financing to Advance R&D and Commercialization of Proprietary Filtration Membranes
ALIOTH
Process Support Technology Product Developer
Efung Capital
Biomedical Professional Investment Institutions
Recently, Alioth Biotech, a leading enterprise in China dedicated to filtration membranes and filters for biopharmaceutical processing applications, announced the completion of a pre-B series financing round exceeding 100 million. This round was led by SDIC Unity Capital, with follow-on investments from Hony Capital, Efung Capital, and Guoshun Investment. Springhill Fund and Yishui Lanshan acted as financial advisors.
This significant capital infusion follows shortly after Alioth Biotech's A++ series financing round in September 2025, which raised over 100 million from Lapam Capital, Sealand Innovation Capital, and Shanghai Xuhui Science and Technology Innovation Investment. The newly acquired funds will be primarily allocated to the ongoing research and development, industrialization, and market expansion of Alioth's self-developed filtration membranes. This successful fundraising strongly demonstrates the market's high recognition of Alioth Biotech's technological capabilities, market position, and development prospects in providing solutions addressing supply chain security challenges within the biopharmaceutical industry.
01.
Strengthening the Foundation for Localization in China's Biopharmaceutical Industry
Against the backdrop of the rapid development of the global biopharmaceutical industry and the increasingly urgent demand for autonomous and controllable supply chains, Alioth has remained dedicated since its establishment to the research, development, manufacturing, and application of critical filtration membranes and single-use filter products essential in biopharmaceutical processes.
Alioth's product portfolio covers key process stages such as sterile filtration, depth filtration, and virus removal filtration. These products serve as core components in ensuring the safety, efficacy, and regulatory compliance of drug production and are characterized by high technological barriers.
For a long time, this market segment has been dominated by international giants. Leveraging deep process understanding, continuous R&D innovation, and a stringent quality system, Alioth has successfully achieved breakthroughs in the localization and scaled production of multiple core product series in China. The performance of these products rivals that of top international standards. Alioth has now become a key strategic supplier to numerous leading domestic biopharmaceutical companies, vaccine manufacturers, and CXO organizations in China, playing a positive role in safeguarding the security and stability of China's biopharmaceutical industry chain.
02.
Funding Drives Capacity Expansion and Global Strategy
This round of capital injection will provide significant momentum for Alioth's next phase of leapfrog development. The funds will be strategically allocated to the following key areas:
Deepening R&D Innovation: Continued increase in R&D investment to expand the new product pipeline, with a particular focus on breakthroughs in high-value-added membrane materials such as virus removal filtration membranes and other cutting-edge directions. This effort aims to strengthen the technological moat and fundamentally address supply chain security challenges for biopharmaceutical process filtration.
Expanding Markets and Applications: Deepening strategic collaboration with domestic clients in China while simultaneously advancing overseas market access and channel development. The goal is to enhance Alioth's brand influence globally and promote high-quality products made with Chinese expertise to serve the worldwide biopharmaceutical industry.
Strengthening the Talent System: Building on its existing core team with international vision, Alioth plans to attract more high-end talent in R&D, marketing, and management. The objective is to form a closely collaborative global execution team to enhance the company's overall competitiveness.
Leveraging this round of financing, Alioth remains committed to achieving independent innovation in upstream key technologies for biopharmaceutical processes and driving the localization of high-barrier products in China. Alioth aims to contribute to securing the biopharmaceutical industry chain and promoting the high-quality development of the sector.
